
Opinion|Videos|August 13, 2024
Measuring Patient Satisfaction with Inflammatory Bowel Disease Treatments and Communication Regarding Treatment Changes
Silvio Danese, MD, PhD; Bruce Sands, MD, and Jean-Frederic Colombel, MD, conclude by sharing their approaches to evaluating patient satisfaction and expectations when providing care for ulcerative colitis and Crohn's disease, while also touching upon the importance of discussing the potential need for escalating or switching therapies to better manage the underlying disease processes.
Advertisement
Episodes in this series

- How do you evaluate patients’ satisfaction and expectations when providing care for UC and CD?
- How do you discuss with patients the idea of escalating/switching therapy, perhaps in the absence of symptoms, and target something they may not feel?
Advertisement
Related to this article

TRANSCEND-T2D-2 topline data show retatrutide lowered A1C more and produced over twice the weight loss of semaglutide 2 mg in type 2 diabetes.

Tom Martens, MD, joins Diana Isaacs, PharmD, and Natalie Bellini, DNP, to discuss CONNECT trial data on CGM in non-insulin-treated type 2 diabetes.

Leigh Ann Pansch, MSN, FNP-BC, DCNP, discusses year-round photoprotection, missed skin cancer detection, and overlooked patients for Healthy Skin Month.

Post hoc analyses at ACAAI 2026 show 41.7% of patients-maintained CSU control and quality of life 16 weeks after stopping omalizumab.

Jasmohan Bajaj, MD, MS, joins Nancy Reau, MD, and Kimberly Brown, MD, on who to screen for HE in clinic and how to prepare patients and families.

Gerard Criner, MD, reviews GOLD 2026 sessions on mucus plugs and inhaler technique, plus multimorbidity, exacerbation risk, and the 2027 GOLD Report.

Dupilumab cut new or worsening allergies by 34% vs placebo in a 12-trial atopic dermatitis meta-analysis, suggesting it may slow the atopic march.
Advertisement
Advertisement
Trending on HCPLive
1
Q&A: Mucus Plugging, Multimorbidity, and GOLD 2027, With Gerard Criner, MD
2
Enlicitide Lowers LDL-C Consistently Across PREVENT CVD Risk Categories
3
Omalizumab Biosimilar CT-P39: Quality of Life Gains Precede CSU Control
4
Diabetes Dialogue: Retatrutide Tops Semaglutide on A1C, Weight in T2D
5

